Evident Vascular Closes Additional Financing for AI-Powered IVUS Platform

March 25, 2025—Evident Vascular, Inc., developer of an intravascular ultrasound (IVUS) platform powered by artificial intelligence and designed to optimize vascular imaging for peripheral and coronary interventions, announced it closed its Series B financing with new investors. Shangbay Capital and two undisclosed strategics are joining founding investor Vensana Capital. 

According to Evident, this additional funding will accelerate the development of the IVUS technology and further support the pathway to FDA 510(k) clearance. 

“This significant investment underscores our investors’ confidence in Evident Vascular’s mission and technology while highlighting the vital role of intravascular imaging in optimizing patient outcomes, clinical decision-making and procedural success,” stated Howard Rosen, CEO and co-founder of Evident Vascular. “We will accelerate our progress toward FDA clearance and further the development of our AI-powered IVUS solution, which aims to set a new standard in vascular image-guided therapy.”